ROMA Score for Ovarian Cancer Risk Assessment
Ovarian cancer is the second most common gynecologic cancer and only 50% of ovarian cancer patients live 10 years after their initial diagnosis. Unlike breast and endometrial cancers where Pap smears and mammograms are available for screening, it is a major challenge for gynecologists to identify ovarian tumors. While identifying an ovarian tumor is difficult in itself, differentiating benign or malignant lesions is even more problematic.
The ROMA (Risk of Ovarian Malignancy Algorithm) is a diagnostic model based on the combined assessment of tumor markers Carbohydrate Antigen 125 (CA125) and Human Epididymis protein 4 (HE4), while taking the menopausal status of the woman into account. CA125 and HE4 are known to increase in cancer involving the ovary, however, the correlation with menopausal status highly differs. The ROMA uses two separate logistic regression algorithms dependent on the menopausal status of the woman to generate a risk score. Several studies and meta-analyses have shown significant diagnostic accuracy of the ROMA score in identifying an unknown adnexal mass as ovarian carcinoma, aiding in the timely diagnosis and intervention of ovarian carcinoma.
- Aid in the diagnosis of ovarian carcinoma
- Aid in the timely application of treatment intervention for ovarian cancer
- As an aid in screening women with an adnexal mass
ROMA Scores are only applicable to female individuals.
ROMA Components:
- Serum CA125 > 46 U/mL: Risk of ovarian malignancy
- Serum HE4 > 140 pmol/L: Risk of ovarian malignancy
# ROMA Score:
Premenopausal women:
- ROMA score < 1.14= Low risk
- ROMA score > 1.14= High risk
Postmenopausal women:
- ROMA score < 2.99= Low risk
- ROMA score > 2.99= High risk
| Marker | Reference Range |
| CA125 | 0-35 U/mL |
| HE4 | <140 |
ROMA score: not applicable for normal women.
Serum (SST).
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Clin Chem Lab Med. 2011 Mar;49(3):521-5. [PMID: 21288178]
- Clin Transl Oncol. 2017 Oct;19(10):1260-1267. [PMID: 28444641]
- Tumour Biol. 2015 Feb;36(2):1045-53. [PMID: 25326813]
- J Obstet Gynaecol. 2018 Nov;38(8):1140-1145. [PMID: 29884096]
- Obstet Gynaecol India. 2020 Jun;70(3):214-219. [PMID: 32476768]